Archive for the ‘Crispr’ Category

CRISPR Therapeutics and Vertex have presented updated data on the first patients treated with their CRISPR/Cas9 gene-editing therapy. The partners now have evidence that one-time treatment with CTX001 improves outcomes in sickle cell disease and beta thalassemia patients for up to 15 months.

In November, CRISPR and Vertex moved the gene-editing field beyond an early milestone by linking the use of CTX001 to sustained improvements in the health and biomarkers of two patients with the severe hemoglobinopathies sickle cell disease and transfusion-dependent beta thalassemia. Late last week, the partners used the European Hematology Association virtual congress to share an update on the studies.

CRISPR and Vertex now have data on two beta thalassemia patients. The first patient, who had nine months of follow up as of last years update, has now been tracked out to 15 months after treatment with CTX001. The patients levels of total hemoglobin, fetal hemoglobin and erythrocytes expressing fetal hemoglobin (F-cells) increased between the two updates.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The partners also have five-month data on a second beta thalassemia patient. The hemoglobin and F-cell levels of the second patient are close to or above those of the first patient at the nine-month mark. Both patients experienced two serious adverse events, none of which the investigator considered to be related to CTX001.

CRISPR and Vertex also used the virtual event to share a nine-month update on a sickle cell patient. Compared to the four-month readout, total hemoglobin and F-cells are up. Fetal hemoglobin is down slightly, but still well above the level likely needed to be efficacious.

The improved biomarker data are supported by evidence the drug is making a meaningful difference to the lives of the patients. The beta thalassemia patients are transfusion independent, having required 34 and 61 units of packed red blood cells a year previously. The subject who required 34 blood units underwent 33 transfusions over the two years before consenting to join the study.

In the sickle cell trial, the patient used to suffer seven vaso-occlusive crises a year, on average. Over the nine months in the study, the patient has been free from vaso-occlusive crises.

The data, which the author of the abstract said demonstrate a functional cure, support the further assessment of CTX001. Efforts to gather more data were hindered by COVID-19, which led to the temporary cessation of elective hematopoietic stem cell transplants at sites in the U.S. and Europe. Some sites are now gearing up to reinitiate dosing.

Even if the restart progresses slowly, CRISPR and Vertex will still be in a position to share more data later in the year. Investigators dosed another three beta thalassemia patients and one sickle cell patient before COVID-19 hit, setting them up to share updates as those subjects pass follow-up milestones.

The updates should also feature longer-term data on the first three patients treated in the trials. In posting long-term data, CRISPR and Vertex will begin to show whether CTX001 has the durability to be a true one-time treatment and, in doing so, carve out a space in a market fought over by rivals such as bluebird bio.

Originally posted here:
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment - FierceBiotech

New Jersey, United States,- A detailed research study on CRISPR and Cas Genes Market recently published by Verified Market Research. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of CRISPR and Cas Genes, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Leading CRISPR and Cas Genes manufacturers/companies operating at both regional and global levels:

CRISPR and Cas Genes Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the CRISPR and Cas Genes market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global CRISPR and Cas Genes market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40530&utm_source=COD&utm_medium=007

CRISPR and Cas Genes Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the CRISPR and Cas Genes market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of CRISPR and Cas Genes Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 CRISPR and Cas Genes Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 CRISPR and Cas Genes Market, By Deployment Model

5.1 Overview

6 CRISPR and Cas Genes Market, By Solution

6.1 Overview

7 CRISPR and Cas Genes Market, By Vertical

7.1 Overview

8 CRISPR and Cas Genes Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 CRISPR and Cas Genes Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/crispr-and-cas-genes-market/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart City ICT Infrastructure Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
CRISPR and Cas Genes Market Analysis, Trends, Top Manufacturers, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards can be truly huge. One such superstar is CRISPR Therapeutics AG (NASDAQ:CRSP), which saw its share price soar 305% in three years. On top of that, the share price is up 62% in about a quarter. But this move may well have been assisted by the reasonably buoyant market (up 30% in 90 days).

View our latest analysis for CRISPR Therapeutics

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

CRISPR Therapeutics became profitable within the last three years. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

We know that CRISPR Therapeutics has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained.

Were pleased to report that CRISPR Therapeutics rewarded shareholders with a total shareholder return of 27% over the last year. But the three year TSR of 59% per year is even better. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example CRISPR Therapeutics has 3 warning signs we think you should be aware of.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.

Visit link:
Shareholders Are Raving About How The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Increased 305% - Simply Wall St

DUBLIN--(BUSINESS WIRE)--The "Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 outbreak, the global market for Molecular Diagnostics has created mixed opportunities for manufacturers all over the world. While some of the application segments, such as infectious diseases, is projected to record the highest growth during the pandemic period of 2019-2022, other applications such as oncology, etc. are estimated to face a reduction in demand during the same period.

The Global Molecular Diagnostics market has generated a revenue of US$10.85 billion in 2019 and is estimated to be just over US$15 billion in 2020. During 2019 to 2022 period, which is said to be influenced by the Covid-19 pandemic, the Infectious Diseases segment is anticipated to gain rapid demand, growing at a robust CAGR of 14.9%. The Infectious Diseases segment, in which Covid-19 testing is a part, is estimated to generate an extra revenue of US$3.8 billion globally in 2020 compared to 2019.

Research Findings & Coverage

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

2. KEY MARKET TRENDS

2.1 Speedier Results Promised by New Test for COVID-19

2.2 COVID-19 Pandemic Takes Korean Testing Kits Demand to New Heights

2.3 New CRISPR-Based Technology Developed for COVID-19 Identification

2.4 Tracing Incidences of Salmonella Food-Poisoning to be Enhanced through New DNA Test

2.5 Molecular Diagnostics of Infectious Diseases Undergo Dramatic Advancements

2.6 Monitoring Treatment of Residual Disease in High-Risk Neuroblastoma Patients Facilitated by Innovative Method

2.7 Time for Diagnosing Sepsis Shortened Significantly Via Novel Next-Generation Sequencing Technique

2.8 Monitoring Antimalarial Drug Resistance Made Easier by Blood Drop Assay

2.9 Silicon Based-Nanostructured Microfluidics - A Novel Molecular Diagnostic Technology for Fetal Aneuploidy

2.10 Creation of Novel and Powerful Adaptive PCR Technique for Rapid Genetic Analysis

2.11 Web Tool Foretells Phenotypes Using little DNA Sample

2.12 Emergence of CRISPR as a Novel Molecular Diagnostic Tool

3. KEY GLOBAL PLAYERS

4. KEY BUSINESS TRENDS

5. GLOBAL MARKET OVERVIEW

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

6. NORTH AMERICA

7. EUROPE

8. ASIA-PACIFIC

9. REST OF WORLD

PART C: GUIDE TO THE INDUSTRY

PART D: ANNEXURE

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7q2nqy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

See the original post:
Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors to 2022 - ResearchAndMarkets.com - Business Wire

(Editors note: This article about a breakthrough technology bootstrapped with a loan from NCBiotech originally appeared Friday, June 12, in the Duke University Medical School online publicationMagnify. Used with permission.)

DURHAM Life scientists love antibodies, not only because these little proteins help protect us all from pathogens, but because antibodies are also a very handy laboratory tool for identifying and marking proteins of interest in their research.

When youre trying to find something very tiny, you need an itty bitty flag to mark it. Thats an antibody.

Like most life science researchers, Duke cell biology chairScott Soderlinghas been reliant on custom antibodies, molecules made-to-order by hundreds of different supply labs that help scientists find and mark specific proteins in cell cultures and living organisms.

But theres a problem, he explains in the small conference room adjacent to his Nanaline Duke office. Fifty percent of the antibodies on the market are junk. Theyre not specific. They might bind what you think they bind, but then they bind to other things you dont know about, or they dont even bind what you want to bind to at all.

Worse than that, one batch of bespoke antibodies may not be the same as the last one. Say you have a perfect antibody that binds exactly what you want and nothing else. And then you order the next lot and theres a different preparation from a different animal, and youre back to square one. It doesnt work.

Scott Soderling. Les Todd photo

Its thought that these bad antibodies lead to a large fraction of the irreproducible results, Soderling says. So it costs money, it costs time and it costs credibility. This is a huge problem for science, both academic and industry. In part, the problem stems from the fact that custom antibody manufacturing techniques date to the 1970s, he says.

But Soderling has founded a Duke spinout company he hopes will solve the reliability problem.CasTag BioSciencesis based on a technology developed in his lab that marks proteins of interest in an entirely new way, using the genome-editing tool CRISPR.

One major thrust of Soderlings research has been identifying proteins in the synapses of the brain, the tiny gaps between nerve cells where signals are transmitted and received. All that signaling is regulated by specific proteins. But identifying all of those proteins in the synapse and interpreting what theyre saying to the cell is a huge problem in a very tiny space. Antibodies are a key tool, but the work has been frustrating and slow, in part because of the difficulty of working with custom antibodies.

About three years ago, as news of the new gene-editing technology called CRISPR spread, Soderling and his team wanted to see if it might give them a better way to label and visualize the hundreds and even thousands of proteins they were detecting in the tiny synapse between neurons.

We had this idea that CRISPR could be a really amazing tool to address the pressing problem of trying to identify and label these hundreds of proteins, Soderling says. What we developed was a new modular method for basically taking the labeling problem and flipping it on its head.

Theyre using CRISPR to edit short sequences into a gene so that every protein it produces carries a tag they have created that is detected by a known, reliable and well-characterized antibody, rather than a shot-in-the-dark custom antibody.

Based on CRISPR gene editing technology, Homology-independentUniversal Genome Engineering, or HiUGE, uses adeno-associatedvirusesto deliver multiple plug and play gene sequencesto a varietyof cellsin a lab dish or a living organism. (The colored neurons in thisimage are in a mouse brain.)

These antibodies recognize a small segment of amino acid sequences, Soderling explains. So we just take the DNA encoding those amino acids the handle and we plop that handle right into the gene in vivo, or in the cell, Soderling says.

After the proof-of-concept experiments produced beautiful protein labeling in the mouse brain, Soderling looked at the images and said, Okay its huge.

Indeed, they dubbed their new system HiUGE (homology-independent universal genome engineering), and it might just be huge indeed.

Theyve taken to calling it plug and play biology, because with just a few of their tags, they can address hundreds of unknown proteins, and they can even put multiple tags into a gene at the same time. Soderling says the system is modular and easy to use, which will enable semi-automated, high-throughput approaches to labeling proteins.

By way of analogy, think of a delivery truck driver going slowly down the block after dark in a downpour looking for house number 2345. What Soderling and his team have done is put a bright sign on every house numbered 2345 that says Hey UPS! Over here!

The HiUGE system is delivered to living cells, either in a dish or in an organism, by a pair of adeno-associated viruses working as a team. One virus carries guide RNA which will mark the spot at which CRISPR should cut the DNA and insert a new piece of code. The second adeno-associated virus carries the payload, a tag or tags theyve devised that will now be built into every protein that gene subsequently produces.

The vectors, including a synthetic guide RNA and HiUGE tags, are agnostic, or homology-independent, as the name implies. They dont care what gene is around them. We designed this guide RNA so that it specifically doesnt recognize anything in the mouse, human, monkey, cat or donkey genomes, Soderling says.

Its a clever way to explore the unknown.

Not only does this approach advance their own work, Soderling began to realize that a fast, flexible, more accurate way to tag proteins might also be a business opportunity. With a little research, he figured out that custom antibodies are a $2.4 billion market again, with products that only work as advertised half the time.

He reached out to Dukes Office of Licensing and Ventures (OLV) to begin the patenting process and to get some advice on starting a company. Then I had to find a way to run the business, because I already have a great day job. In fact, he had also just been named chair of cell biology at about the same time.

At OLVs recommendation, Soderling visited Biolabs North Carolina, a shared workspace in the Chesterfield Building in downtown Durham which leases individual wet-lab benches on a month-to-month basis and provides all the basic equipment a startup would need, including refrigeration, gene-copying PCR machines, centrifuges, etc. He pitched his idea to Biolabs and had a look around.

The next day, BioLabs NC president Ed Field called Soderling and asked if hed like some help running the business. Field, a startup veteran, is now the CEO of CasTag. The firm has raised enough money with a loan from the North Carolina Biotechnology Center to hire a recent Fuqua Business School graduate as the business development lead and a former postdoc for Soderling to run the lab part-time while he looks for a job in industry.

Weve got a website. Weve got orders. Weve got customers. Its up and running, Soderling says, with a measure of wonder in his voice. His conference talks about HiUGE and a July 1, 2019 paper in Neuron attracted some attention. Then the paper was republished as one of the journals best of 2018-2019, drawing still more notice.

And now they also have ideas for new products. Im hoping that this will expand and become even bigger than just tagging proteins, Soderling says.

You know, North Carolina was a manufacturing state back in the day, says Soderling, a soft-spoken native Tennessean. I would love to wake up some day and drive into downtown Durham and see one of the former manufacturing warehouses humming away with people making these reagents to ship out around the world. Thats the dream.

Durham academic research services companyResearch Squarehas producedthis 3 1/2-minute Vimeo videoexplaining the CasTag BioSciences technology.

(c) North Carolina Biotechnology Center

Go here to see the original:
Duke spinout CasTag BioSciences builds a better protein trap with boost from NCBiotech - WRAL Tech Wire

[269 Pages Report] Mice Model Market report categorizes the Global market by Type (Inbred, Knockout, Hybrid), Technology (CRISPR, Microinjection), Application (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) & Geography. COVID-19 impact on Mice Model Industry.

MarketsandMarkets forecaststhemice model marketto grow from USD 1.11 billion in 2016 to USD 1.59 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.5%during the forecast period. The growth of the market can be attributed to ongoing innovations in mice models, continuous support in the form of investments and grants, and growing demand for humanized mice models.

By Technology, the CRISPR technology segment to account for the largest share of the global mice model market in 2016

Based on technology, the market is segmented into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. The CRISPR technology accounts for the largest share of the global mice model market in 2016.

The large share of this segment can primarily be attributed to the fact that CRISPR is the most widely used technique due to the various advantages associated with it, such as ease of design, high efficiency, and relatively low cost.

Emergence of CRISPR as a powerful tool in the field of biomedical research

CRISPR (clustered, regularly interspaced, short palindromic repeat) is seen as a revolutionary technology for gene editing. The use of Cas9 enzyme differentiates CRISPR from other forms of genetic modification.

This technology edits and rearranges genes by cutting out damaged or unwanted parts of the DNA, allowing the remaining DNA to be rearranged in a new way.

Moreover, this fast, precise, and easy-to-use technology is considered as a revolutionary tool in research, and there is an intense interest to validate its therapeutic usage in humans.

CRISPR was first shown to work in mouse and human cells less than three years ago and has already been applied to a range of biological systems and disease areas. CRISPR is used in the development of genetically modified mice strains, making the process not only quicker but also less expensive.

Thus, the emergence of CRISPR as a popular technology is expected to offer potential growth opportunities in the coming years.

Download PDF Brochure @www.marketsandmarkets.com/pdfdownsp?id=1308

North America to account for the largest market size during the forecast period.

North America is accounted for the largest share of the market. North Americas leadership in the market can be attributed to the increased focus on biomedical research in the U.S., rising demands for monoclonal antibody production, nexus between CROs and pharmaceutical companies, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

Asia Pacific is the third-largest market for mice model market and is slated to register the highest CAGR of 7.9% during the forecast period. The high growth in the region can be attributed to less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost the biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical & biotechnology R&D activities.

Key Market Players

Charles River Laboratories International, Inc. (U.S.), The Jackson Laboratory (U.S.), Taconic Biosciences, Inc.(U.S.), TRANS GENIC Inc. (Japan), Horizon Discovery Group plc (U.S.), Envigo (U.K.), Laboratory Corporation of America Holdings (U.S.), and genOway (France).

Charles River Laboratories is a leading player in the global mice models and services market. The mice models offered by the company include inbred, outbred, hybrid, immunodeficient, congenic, and genetically engineered mice.

The company also offers mice modeling services such as surgical services for rodents, genetic testing services, colony management services, and health monitoring services. The strong portfolio enables the company to increase collaboration with clientsfrom early lead generation to candidate selection.

Request for Sample Pages @www.marketsandmarkets.com/requestsp?id=1308

Recent Developments

Critical questions the report answers:

Inquiry About Mice Model Market @www.marketsandmarkets.com/Enquirysp?id=1308

This email address is being protected from spambots. You need JavaScript enabled to view it.

Link:
Explore the Mice Model Market: CRISPR As a Powerful Tool in the Field of BioMedical Research - WhaTech Technology and Markets News

Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

bluebird bio Data from a Phase I/II study of Cambridge, Mass.-based bluebird bios gene therapy treatment LentiGlobin in adult patients with sickle cell disease has shown a show a near-complete reduction of serious vaso-occlusive crises (VOCs) and acute chest syndrome (ACS), the company said. VOCs are life-threatening episodes that are the primary manifestation of sickle cell disease. A nearly complete elimination of this demonstrates the potential of LentiGlobin in this indication, David Davidson, the chief medical officer at bluebird said in a statement. Data from the Phase I/II study showed a 99.5% reduction in the annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome in patients. Two years after those patients remained free from VOCs and ACS, bluebird said.

These results illustrate the type of outcomes we believe are needed to provide truly meaningful improvements for people living with sickle cell disease. In addition, the improvement of laboratory measures of hemolysis and red cell physiology, with nearly pan-cellular distribution of the anti-sickling HbAT87Q, suggest LentiGlobin for SCD may substantially modify the causative pathophysiology of SCD, he said.

Based on these results, bluebird said it plans to seek an accelerated approval from the U.S. Food and Drug Administration for LentiGlobin in this indication.

Additionally, bluebird released data from its Phase III study of betibeglogene autotemcel (formerly LentiGlobin gene therapy for -thalassemia) in transfusion-dependent -thalassemia. Data showed the majority of patients achieved transfusion independence and were able to maintain it with near-normal hemoglobin levels, bluebird said.

CRISPR Therapeutics Working with its partner Vertex Pharmaceuticals, CRISPR Therapeutics presented new clinical data for CTX001, an investigational CRISPR/Cas9 gene therapy, from the CLIMB-111 and CLIMB-121 Phase I/II trials in transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease, respectively. In the CLIMB-111 trial, data demonstrated clinical proof-of-concept for CTX001 in TDT based on the first patient dosed. Updated data presented at the conference showed that 15 months following treatment with CTX001, the patient was transfusion independent. Data from the second patient treated with CTX001 was also promising. After five months, the patient was transfusion independent. Both patients experienced serious adverse events, but they were determined to not be related to the treatment.

In the CLIMB-121 trial, the data showed that nine months after CTX001 infusion, the patient was free of VOCs, transfusion independent and had improved hemoglobin levels. The patient that formed the basis for this early study also experienced SAEs, but they were determined to not be related to the treatment.

ADC Therapeutics Less than a month after it closed on a $267 million IPO, ADC Therapeutics announced updated data from its pivotal Phase II study of the companys lead candidate loncastuximab tesirine (Lonca) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at the conference. The company also presented interim results from its Phase I/II trial of Lonca in combination with ibrutinib. In the Phase II LOTIS 2 study, ADC said Lonca demonstrated anti-tumor activity and durability in a broad population of difficult-to-treat patients with relapsed or refractory DLBCL. Data showed that Lonca provided an overall response rate of 48.3% and a complete response rate of 24.1%. The study also showed a median duration of response of 10.25 months. The company said Lonca had a manageable toxicity profile. ADC Therapeutics is on track to submit a BLA to the FDA for Lonca in the second half of this year and, if approved, the company plans to launch the product sometime in mid-2021.

ADC also noted at the conference that interim results from the Phase I/II LOTIS 3 study of a combination of Lonca and Janssens Imbruvica (ibrutinib) demonstrate the potential of Lonca to be used for earlier lines of therapy in combination with other therapies in patients with relapsed or refractory DLBCL or mantle cell lymphoma. Interim data showed an ORR of 66.7% and a CRR of 50%, ADC noted.

Apellis Pharmaceuticals Waltham, Mass.-based Apellis presented results from its Phase III PEGASUS study at the conference that showed detailed data from the results first released in January, which showed superiority for pegcetacoplan over eculizumab in improving hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria (PNH). New data from the pivotal study showed that pegcetacoplans effect was seen consistently across the study population, both in patients who had low or no transfusion requirements and high transfusion requirements. Pegcetacoplan also demonstrated a robust response across several key hematologic and clinical measures for PNH. The study showed that 71% of pegcetacoplan-treated patients achieved LDH normalization in comparison to 15% of eculizumab-treated patients. Additionally, 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score in comparison to 0% of eculizumab-treated patients, the company said.

With the strong results in hand, Apellis plans to submit a New Drug Application to the FDA and a Marketing Authorization Agreement to the European Medicines Agency for pegcetacoplan for the treatment of PNH in the second half of 2020.

Takeda Takeda Oncologyannouncedpositivedata from two studies of Ninlaro,an oral proteasome inhibitorthatis being studied across the continuum of multiple myeloma treatment settings. Phase III data from theTOURMALINE-MM4trialdemonstrate thattreatment with NINLARO resultedin a statistically significant and clinically meaningful improvement inprogression-free survival (PFS).This corresponds to a 34% reduction in the risk of progression or death in patients treated with Ninlaro.

Additionally, Takeda reported that real-world data from theUS MM-6studyrevealed thein-class transition from treatment with parenternal bortexomibto an oralNinlaro-based treatment resulted in an increase in overall response rate from 62% to 70% and an increase in complete response from 4% to 26%.These data suggest promising efficacy without impacting patients quality of life, with treatment taken by patients at home, the company said.

Read the original:
European Hematology Association Meeting Kicks Off with Strong Data Presentations - BioSpace

The cultivation of grapes in Europe, whose acreage represents 3% of the total cultivable acreage, accounts for up to 65% of the pesticides used by EU growers, given the high incidence of powdery mildew and mildew in the productions. However, this percentage could be drastically reduced if the EU opted for the most advanced plant reproduction technologies, such as CRISPR, which would make it possible to obtain grape varieties resistant to both fungi.

Thus, research has been carried out in this field for several years in order to improve European grape varieties. In the case of Italy, in 2015, ten genetically edited grape varieties were registered in the National Variety Catalog, and in 2018, the first field harvests were carried out. Although still in the pre-commercial phase, the results so far have been positive in terms of resistance to diseases.

The researchers hope that the regulatory uncertainty of CRISPR technologies will be resolved (they are subject to the same regulations as transgenics, despite not being the same). They also hope that both producers and consumers will learn about the potential of these techniques to tackle the agro-food and environmental challenges that humanity is facing.

Source: agronewscastillayleon.com

Read more:
Genetic editing of grapes by CRISPR could reduce the use of pesticides in Europe - FreshPlaza.com

There is new hope for cat lovers who are allergic to their pets. Rather than desensitizing the human, researchers are working to eliminate the Feld1 protein, the primary allergen, from the cat, using CRISPR-Cas9 gene-editing technology.

"One of the benefits of CRISPR, compared to other methods of tackling this problem, is that you can permanently remove Feld1, compared with other techniques that only reduce the allergen," said Nicole Brackett, PhD, from Indoor Biotechnologies.

Previous attempts to remove the allergen have included feeding cats a specially formulated food that reduces Feld1 in the saliva, so less ends up on the dander when they lick themselves, as reported by Medscape Medical News.

"We hope to get to a point where we can offer an injection, or a series of injections, you would get at the vet, which would make the cat allergen-free," said Brackett, who presented the research in a poster at the European Academy of Allergy and Clinical Immunology 2020 Digital Congress.

When you're using this kind of technology, you are taking on a tremendous amount of responsibility.

About 10% of humans are allergic to cats, and we see the ones who are affected by their own cats, said Dean Mitchell, MD, an allergist and immunologist from Mitchell Medical Group in New York City.

"This research is interesting, but when you're using this kind of technology, you are taking on a tremendous amount of responsibility," he told Medscape Medical News.

"It's really an exciting technology, but I think it's scary, altering genes," he said. "You never know what you're going to change. Maybe we should use it to cure COVID first."

For their study, Brackett and her colleagues used discarded tissue samples from 50 spayed and neutered cats to collect genomic DNA from the Feld1 chains1 and 2.

The first goal was to see how similar genes were between cats, she explained. "We wanted to target a region in the gene that is well conserved something you would see in all cats not a random mutation."

The researchers were able to sequence a panel of 10 guide RNAs and use CRISPR Cas-9 to edit the genes. "We now have proof of principle in a cat cell line," Brackett told Medscape Medical News.

We still have a long way to go, but should have something we can test in a cat in a couple of years. But, she acknowledged, "we still don't know the role of the protein in the cat."

Feld1 expression differs from cat to cat, Brackett pointed out. "Some cats have an abundance and some have very little. The expression can vary, even within one cat."

Speculation on the function of Feld1 also varies. Because it's produced in the sebaceous gland, "it may serve as a way to coat, or protect, the skin. Or maybe it has something to do with chemical communication, maybe to communicate with other cats," she said. "But the fact that we see so much Feld1 variability with no obvious correlating behaviors makes us think it's not essential. One of the benefits of our study is we may figure that out."

Her lab is also looking at Feld1 expression in wild cats to determine its origin from an evolutionary standpoint. "We are curious to see how this allergen has evolved in different species of cats," she explained.

Cat allergies "rank number two in frequency and seriousness of allergies after food allergies, causing people to need to be on steroids or medications," Mitchell told Medscape Medical News. "Fifty percent of my immunotherapy practice is cat or dog allergy; it's a significant problem."

Young kids can't play at their friend's houses, relationships are affected, and families have to choose between their beloved cat and a healthy family member, he said.

Sublingual immunotherapy of Feld1 has been proven effective in clinical trials and is common in Europe, but "only about 100 allergists in the United States offer it," Mitchell said. "It's been a very underappreciated therapy, and I really don't know why; maybe because it's not patentable by a drug company."

Sublingual drops are not covered by insurance, and the therapy runs about $120 per month in the United States. "I've helped hundreds of patients with it," said Mitchell, and usually the therapy significantly improves patient quality of life.

The fact is, people make major life choices based on their cats, Mitchell explained.

One of his pollen-allergic patients who loved both her cat and her cat-allergic boyfriend told him that her boyfriend wouldn't sleep over. "Can you help him?" she asked.

"The first day I see him, he's wheezing and can't breathe." Mitchell recalled. He treated the boyfriend with sublingual Feld1 immunotherapy. "After 4 or 5 months, he could go over to her house using inhalers on weekends sometimes. A year later, they moved in together and got married. The cat even slept on the bed at the end.

Mitchell discharged the boyfriend after 3 years of treatment. He ran into him on a New York sidewalk a couple of years later and asked how he was doing. It turned out the couple had gotten divorced.

"That's too bad, I told him. But at least you don't have to deal with the cat anymore," Mitchell recalled.

"Oh no, I liked the cat too much, he stayed with me," his patient told him.

Mitchell laughed. "You just can't make this stuff up!"

Brackett works for Indoor Biotechnologies as a scientist. Mitchell has disclosed no relevant financial relationships.

European Academy of Allergy and Clinical Immunology (EAACI) 2020 Digital Congress

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Go here to see the original:
More Than One Way to Fix Cat Allergy - Medscape

Join us on Friday, June 19, to find out how massively parallel microbial strain engineering may lead to the development of novel therapeutics to combat the most difficult antibiotic-resistant pathogens

Massively parallel microbial strain engineering on a CRISPR-based benchtop platform has enabled the exploration of the genetic dependencies of antibiotic function in unprecedented scale and detail. The ability to design and deliver precisely determined edits throughout the entire E. coli genome has resulted in an unparalleled opportunity to query a diverse population of strain variants for their growth responses to antibiotics from multiple different functional classes.

Find out more in this expert webinar as Dr. Dan Held, Director of Synthetic Biology, Microbial Applications Development, Inscripta, outlines how the knowledge garnered through the use of this strain engineering technology has significant potential to lead to the development of novel therapeutics against our most difficult antibiotic-resistant pathogens.

Key learning objectives

Who should attend?

This webinar will run on Friday, June 19, 2020, at:

Register to watch the full webinar here>>

SelectScience runs 3-4 webinars a month across various scientific topics,discover more of our upcoming webinars>>

Original post:
Expert Insight: Discover the genetic dependencies of antibiotic function - SelectScience

The market research on Global CRISPR-Based Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025 presents an in-depth analysis of market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data. The report aims to identify the dynamics of the global CRISPR-Based Therapeutics market and provide recent updates and insights that affect various segments of the global market. The market report sorts the market dependent on the manufacturer, region, type, and application. The report estimates and validates the market size of the global CRISPR-Based Therapeutics market. The report also delivers a forecast, which focuses on the market opportunities for the next five years (2020-2025) for each region. The scope of the study segments the global market by product type, application, end-use, and the region is explained. This research report is expected to enable clients to assess strategies deployed by market leaders.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/41907

Company Profiles:

The report provides immense detailing on each and every company. It incorporates their headquarter location, company overview, recent developments, and company strategies. Market share analysis as per different companies, market forecast, demand, price analysis, size, and share as per regional boundaries has been presented in the report. The report gives a study on global CRISPR-Based Therapeutics industry-top players depending on their company profile, product portfolio, ability, cost, and revenue.

Key market players: Caribou Biosciences , Thermo Fisher Scientific , Merck KGaA , Addgene , Takara Bio USA , CRISPR THERAPEUTICS , Intellia Therapeutics , Editas Medicine , Mirus Bio LLC , Horizon Discovery Group , GE Healthcare Dharmacon

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type: Genome Editing, Genetic Engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-crispr-based-therapeutics-market-41907

Regional Analysis of The Market:

The report represents all the regions as well as countries across the globe, which showcases a regional manufacturing status, such as volume, market size, value, and price details. Regional analysis is given by tracing the historical forecast market size. It provides complete information about the key developed regions as well as major emerging markets depending on the regional growth of the global CRISPR-Based Therapeutics industry. The anticipated development rate to be recorded by every locale over the conjecture years has been expressed in this report. In terms of geography, the report highly focuses on showcase development, development rate, and development potential. The report studies key players and provides a five-year annual trend analysis, which highlights market size, volume, and share for North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East& Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Continue reading here:
Global CRISPR-Based Therapeutics Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 - Jewish Life News

The new market report on CRISPR and Cas Genes is a comprehensive study providing analysis on factors trend and drivers contributing to growth of the Biotechnology. The report is prepared with reference to historic data .Estimation of contribution of segment is expressed in terms of volume and revenue for the forecast period. Market analysis and future prospect is segmented in various sections. Each sections focus on distinct features of the products that are anticipated to shape the market over the forecast period.

Some of the common segments mentioned in the report include market overview, tends, drivers, opportunities, restraints, regional segment, end-use application, and competitive landscape. The global revenues in CRISPR and Cas Genes market are projected to scale at a CAGR of 21.2% between 2020 and 2026.

Many stakeholders are consistently adopting new methodologies to boost growth of the market. Few investors are investing on research and development of new products, on the other hand, various companies are innovating the existing products.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

In the wake of lockdown across various regions due to outbreak of COVID-19 pandemic, vendors in CRISPR and Cas Genes are focusing to enhance their customer reach using e-commerce channels.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The regional segmentation of the CRISPR and Cas Genes market is done as follows:

On the basis of product types, the CRISPR and Cas Genes market report offers insight into major adoption trends for the following segments:

Key end-users covered in the study include:

To Know More Information about This Report, Ask The Analyst: https://www.factmr.com/connectus/sample?flag=AE&rep_id=4823

Companies profiled in the report are:

How can Fact.MR Make Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

The rest is here:
Impact of COVID-19 on CRISPR and Cas Genes Market, Infers Fact.MR - The Cloud Tribune

Last year, a bioengineer assistant professor at Stanford University named Stanley Qui used a gene-editing tool called CRISPR, which flights influenza, to develop their own technique called Prophylactic Antiviral CRISPR in human cells. Also known as PAC-MAN, a team from Stanford University now works alongside Berkeley's Molecular Foundry to see if they can apply the same technique to fight against coronavirus.

As the first case of SARS-CoV-2, Qi and his team thought, 'Why don't we try using our PAC-MAN technology to fight it?' By late March, the Stanford scientists collaborated with Michael Connolly, an engineer of the Biological Nanostructures Facility at Berkeley Lab's Molecular Foundry, so they can develop a new system that can deliver PAC-MAN into patients' cells.

The first CRISPRsystem was discovered by Yoshizumi Ishino from Osaka University in 1987. Repeating clustered DNA was observed to have interruptions in what would typically be consecutively arranged.

By 2001, Ruud Jansen, searching for interrupted repeats, coined the term Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). His observation of the prokaryote repeat cluster being accompanied by homologous genes resulted in cas genes.

PAC-MAN is made up of the enzyme Cas13, a virus killer, and a strand of guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus's genome. By re-arranging COVID-19's genetic code, PAC-MAN could neutralize it and stop it from replicating internal cells.

Qi explained that the primary challenge of translating PAC-MAN from a molecular tool into an anti-virus therapy is finding an effective way to deliver it into respiratory cells. As SARS-CoV-2 invades the lungs, infected air sacs become inflamed and filled with fluid, causing difficulty in breathing."But my lab doesn't work on delivery methods," he said, as the lab posted a tweet in hopes of finding the right collaboration.

By late March, they learned about Connolly's work on synthetic molecules, or lipitoids, and needed his expertise in cellular delivery techniques. Lipitoids are synthetic peptide mimics or peptoids. Connolly has worked with Ron Zuckermann, his mentor who discovered the peptoid, for 20 years to demonstrate 'lipitoids' effectiveness in the delivery of DNA and RNA to a wide variety of cell lines'

Read Also: HK Airport's Disinfection Booth Claims to Kill Coronavirus Using Nano Needle in 40 Seconds

In May 2018, scientists studying lipitoids for potential therapeutic applications resulted that it is not harmful to the body and can deliver nucleotides by encapsulating them in nanoparticles the same size as a virus. Qi now hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundry's growing body of lipitoid delivery systems.

In late April, they tested a type of lipitoid, Lipitoid 1, which self-assembles with DNA and RNA into PAC-MAN carriers in a human epithelial lung cell sample. The initial trial went well as the SARS-CoV-2-targeting PAC-MAN reduced the synthetic solution by more than 90%. 'Berkeley Lab's Molecular Foundry has provided us with a molecular treasure that transformed our research,' Qi said.

Scientists from New York University and Karolinska Institute in Stockholm, Sweden will be joining the collaboration as they plan to test the PAC-MAN/lipitoid system in a live animal model infected with the virus. If successful, they may proceed to preclinical tests.

Conolly explained that 'an effective lipitoid delivery, coupled with CRISPR targeting, could enable a very powerful strategy for fighting viral disease not only against COVID-19 but possibly against newly viral strains with pandemic potential.' 'Everyone has been working around the clock trying to come up with new solutions," added Qi. 'It's very rewarding to combine expertise and test new ideas across institutions in these difficult times.'

Read Also:Meet Xenobots: World's First Living and Self-Healing Robots Using Stem Cells From Frog Embryos

See the rest here:
PAC-MAN vs COVID-19 - Scientists Are Developing Gene-Targeting Technology to Beat the Virus - Science Times

Imagine a world in which we can produce meat without animals, cure previously incurable diseases by editing an individuals genetic fabric, and manufacture industrial chemicals in yeast factories. The foundational technologies that could make all this possible largely exist. Rapid and ever-cheaper DNA sequencing has deepened our understanding of how biology works and tools such as CRISPR are now being used to recode biology to treat diseases or make crops less vulnerable to climate change. This is what we call the Bio Revolution.

Explored in a new McKinsey Global Institute research report, which we helped co-author, the Bio Revolution is already benefiting society. A confluence of breakthroughs in biological science and ever faster and more sophisticated computing, data analytics, and artificial intelligence technologies has powered scientific responses to the Covid-19 pandemic. Scientists sequenced the virus genome in weeks rather than months, as was the case in previous outbreaks. Bio innovations are enabling the rapid introduction of clinical trials of vaccines, the search for effective therapies, and a deep investigation of the transmission patterns of the virus.

The report estimates that bio innovations could alleviate between 1% and 3% of the total global burden of disease in the next 10 to 20 years from these applications roughly the equivalent of eliminating the global disease burden of lung cancer, breast cancer, and prostate cancer combined. Over time, if the full potential is captured, 45% of the global disease burden could be addressed using science that is conceivable today.

advertisement

As much as 60% of the physical inputs to the global economy today are either biological (such as wood for construction or animals bred for food) or nonbiological (such as cement or plastics) but could, in principle, be produced over time using biology. Nylon can already be made using genetically engineered yeast instead of petrochemicals, for instance, leather is being made from mushroom roots, and bacteria have made a type of cement.

This Bio Revolution has the potential to be as transformative to business and economies as the Digital Revolution that proceeded it, creating value in every sector, disrupting value chains, and creating new business opportunities. Businesses clearly see the potential investment in a new generation of biological technologies had already surged to more than $20 billion by 2018.

advertisement

Many applications are being commercialized. We identified a visible initial pipeline of about 400 use cases, almost all scientifically feasible today, that could create a direct economic impact of $2 trillion to $4 trillion in the next 10 to 20 years more than half of which is outside health, in sectors as diverse as agriculture and textile manufacturing.

The confluence of biology and computing is already creating new capabilities. Computing is accelerating discovery and throughput in biology. An explosion of biological data due to cheaper sequencing is being used by biotech companies and research institutes that are increasingly using robotic automation and sensors in labs. Biotech company Zymergen, for example, has found that throughput in biological screening can be increased up to 10 times. Advanced analytics, more powerful computational techniques, and AI are also being deployed to generate more acute insights during the R&D process.

New biology-based manufacturing is already cutting costs, improving performance, and reducing the impact on the environment and the natural world. In cosmetics, for instance, Amyris is now making squalane, a moisturizing oil used in many skin-care products, by fermenting sugars using genetically engineered yeast instead of processing liver oil from deep-sea sharks, which was not only expensive but threatened the species with extinction. In textiles, U.S. startup Tandem Repeat is producing self-repairing, biodegradable, and recyclable fabric using proteins encoded by squid genes.

The Bio Revolution could utterly change the food business as plant-based proteins and lab-grown meat gain popularity and in the process cut greenhouse gas emissions from deforestation and animal husbandry. One study found that cultured meat could reduce greenhouse gas emissions by 80% or more compared with conventional meat if all of the energy used in manufacturing comes from carbon-free sources.

Cultured meat and seafood are made using tissue-culture technology, a lab process by which animal cells are grown in vitro. Producers still face a major technical challenge in finding a cost-effective way of growing cells. New players such as Finless Foods, Mosa Meat, Memphis Meats, and Meatable are experimenting with different approaches, including using synthetic molecules and pluripotent stem cells to replace expensive growth factors. Cultured meat and seafood could be cost-competitive with conventional animal production systems within 10 years.

In agriculture, greater understanding of the role of the microbiome offers opportunities to improve operational efficiency and output. By profiling bacteria and fungi in the soil, Trace Genomics, for one, produces insights that help choose tailored seeds and nutrients, and enables early prediction of soil diseases. In consumer markets, ongoing research into the relationship between the gut microbiome and the skin is being used to personalize skin care. Singapore-based genomics firm Imagene Lab, for instance, offers a personalized serum based on the results of its skin DNA tests that assess traits such as premature collagen breakdown.

Such examples give a sense of the breadth of applicability of bio innovation, but there is a significant caveat: risk. Biology will preserve life through innovative treatments tailored to our genomes and microbiomes, but biology could also be the greatest threat to life if it is used to create bioweapons or genetically engineered viruses that can do lasting damage to the health of humans or ecosystems. The CRISPR gene-editing tool is revolutionizing medicine and is being applied to agriculture with great effect. But consider that CRISPR kits are now available to buy on the Internet for $100 and so-called biohackers are using them at home.

Like the Digital Revolution, the Bio Revolution comes with risks but of a different order of magnitude. If citizens already have misgivings about data being gathered about their shopping habits, how much more nervous will they be about genetic data gathered from their bodies for medical treatment or ancestry tracing data that couldnt be more personal.

Another risk is that biological organisms are, by their nature, self-sustaining and self-replicating. Genetically engineered microbes, plants, and animals may be able to reproduce and sustain themselves over the long term, potentially affecting entire ecosystems. Once Pandoras box is opened and we have already cracked the lid we may have little control over what happens next.

Unless such risks are managed, it is possible that the full potential of the Bio Revolution may not materialize. We estimate that about 70% of the total potential impact could hinge on societal attitudes and the way innovation is governed under existing regulatory regimes. Yet if the risks can be managed and mitigated, the Bio Revolution can reshape our world. Scientists, in conjunction with forward-thinking companies, are now harnessing the power of nature to solve pressing problems in medicine, agriculture, and beyond, and helping craft a response to global challenges from pandemics to climate change.

Matthias Evers is a senior partner and global leader of research and development in McKinsey & Companys pharmaceuticals and medical products practice. Michael Chui is a partner at the McKinsey Global Institute, McKinseys business and economics research arm.

Read the original post:
The Bio Revolution is changing business and society - STAT - STAT

A new market report by Market Research Intellect on the CRISPR And CRISPR-Associated (Cas) Genes Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the CRISPR And CRISPR-Associated (Cas) Genes sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=207429&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading CRISPR And CRISPR-Associated (Cas) Genes manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The CRISPR And CRISPR-Associated (Cas) Genes Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207429&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of CRISPR And CRISPR-Associated (Cas) Genes. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=207429&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the CRISPR And CRISPR-Associated (Cas) Genes market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:
CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026...

Scientists and researchers around the world are working round the clock to fight the COVID-19 pandemic. Gene editing using CRISPR is one such recent study.

In 2019, Assistant Professor Stanley Qi and his team in the departments of bioengineering and chemical and systems biology at Stanford University began working on a technique called PAC-MAN to fight influenza. PAC-MAN stands for Prophylactic Antiviral CRISPR in human cells and uses the gene-editing tool called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.

The research team didnt know then that their technique could be used in fighting the global pandemic like COVID-19. When the pandemic emerged in Jan, the team decided to use their PAC-MAN technology to fight it. In collaboration with a group led by Michael Connolly, a principal scientific engineering associate in the Biological Nanostructures Facility at Berkeley Labs Molecular Foundry, the researchers have been developing a system to deliver PAC-MAN into the cells of a patient since March. Their preprint paper was recently peer-reviewed and published in the journalCell.

Read Also: New link found between heart failure medicine and virus responsible for mono, some cancers

Like all CRISPR systems, PAC-MAN comprises of the virus-killing enzyme Cas13 and a strand of guide RNA. The guide RNA commands Cas13 to destroy specific nucleotide sequences in the coronaviruss genome, effectively neutralizing it and stopping its replication.

Every gene-editing tool needs an efficient delivery system to deliver them to the molecular or cellular level. According to Qi, their lab doesnt work on cellular delivery methods, and Connollys work on synthetic molecules called lipitoids at the Molecular Foundry came to their rescue. Lipitoids were first discovered 20 years ago by Connollys mentor Ron Zuckermann is a type of synthetic peptide mimic known as a peptoid. In the decades since the discovery, Connolly and Zuckermann have developed peptoid delivery molecules such as lipitoids.

Qi hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundrys growing body of lipitoid delivery systems. Their late April tests performed well. When packaged with coronavirus-targeting PAC-MAN, the system reduced the amount of synthetic SARS-CoV-2 in solution by more than 90%. The team is planning to conduct further tests in an animal model against live SARS Coronavirus-2.

Read Also: SARS-CoV-2 transmission does not fasten due to mutation, study says

If the tests prove successful, the team hopes to continue working with Connolly and his team to develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses. And also, explore options to scale up for a clinical trial.

The research is highly significant. It would be a powerful strategy to fight not just coronaviruses but possibly against new viral strains that can become a pandemic.

Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!

Source: Phys.org, Berkeley Lab

See the rest here:
A breakthrough in Gene Editing to help in the fight against COVID-19 - News Landed

As the coronavirus pandemic continues to threaten public health, scientists throughout the world have been working around the clock to develop effective treatments against COVID-19. CRISPR gene editing is one of the techniques researchers are using. During the Virtual Regeneron International Science and Engineering Fair (ISEF), Tina Hesman Saey, Senior Writer and molecular biology reporter at Science News, spoke with Feng Zhang (ISEF 1998-1999, STS 2000), one of the pioneers of CRISPR technology, about CRISPRs role in fighting COVID-19.

Feng shared three main ways CRISPR is being used to fight COVID-19:

Students asked whether human genes could be modified as another possible defense against the coronavirus. Before editing the human genome can occur, however, Feng cautioned we must first better understand how the virus works. The idea of engineering CRISPR into our own cells to fight the virus is a ways off, he stated. Wed have to find out more about the way CRISPR proteins behave in the body and how we can use them safely.

Given the scope of the coronavirus pandemic, Feng finds it very encouraging to see scientists, technologists and companies collaborating now more than ever. We are facing one common problem and we need to work together to provide as many solutions as possible, he noted. As some researchers work on a vaccine, others are developing at-home tests to scale up testing capacity. Manufacturers are supporting these efforts by producing more reagents, the chemical compounds tests depend on to deliver results. What is really promising is that all these different aspects are being addressed, he lauded.

The level of teamwork Feng has witnessed within the scientific community during this global crisis reminds him of the same collegiality he encountered as a student. You can strike up conversation with anybody at a science fair, he said. Competing in both STS and ISEF were transformative experiences for Feng. He made many friends that he still interacts with today, even occasionally working on projects with people he met then.

Looking ahead, what can students do to help facilitate research on COVID-19? Reach out to people who are working on things you find interesting, Feng advised. Youll be surprised to find there are many ways you could be engaged and contribute. With epidemiologists analyzing public health data, scientists seeking to gain a molecular understanding of the virus and others studying its origins, just to name a few areas, there is ample opportunity to get involved and make a positive difference.

If you missed this session, it can be viewed in full on our online platform through June 5. Register here.

Visit link:
ICYMI: The role of CRISPR in the fight against COVID-19 - Science News for Students

Conservation biology is plagued by cases of mistaken identity. Salamanders that look exactly the same turn out to live a continent apart. A group of seemingly homogenous eels is actually two different types. New species of fungi hide in plain sight, disguised as ones we know well.

So in 2017, when California Department of Water Resources animal scientist Melinda Baerwald read about a tool that could quickly differentiate between similar viruses and bacteria, I just thought, oh my gosh, she says. The tool, called SHERLOCK, was developed by biochemists, and uses CRISPR technology, which has already revolutionized medical research. Dr. Baerwald thinks it could have a similar effect on conservation biology by enabling fast, low-cost species identification in the lab or in the field. In a new paper in Molecular Ecology Resources, Dr. Baerwald and colleagues describe how they used the technology to build tests that can differentiate between species doppelgngers.

Dr. Baerwald and her colleagues used SHERLOCK to develop two slightly different identity tests. Both rely on CRISPRs ability to recognize particular segments of DNA, which allows the tests to answer yes or no questions: not What kind of bear is this? for example, but rather, Is this a polar bear? The first type of test, which is done in a tube, involves a reagent that fluoresces when it comes into contact with the target DNA, and takes about 20 minutes. The second requires less equipment, and works more like a pregnancy testa positive identification shows up as a band on a test stripbut takes slightly longer, and is a little more expensive.

They then tested the tools on three species of fish: delta smelt, longfin smelt, and wakasagi. All three look quite similar at the larval stagetranslucent and wrigglyand all three live in the San Francisco Estuary, where they are frequently mistaken for one another. (A 2018 study found that 27% of supposed wakasagi sampled during a monitoring survey were actually delta smelt.) But the delta smelt is federally threatened and the longfin smelt is endangered in the state of California, while the wakasagi is an introduced species without any special protections.

After using them on dozens of samples of fish whose species had been determined by other means, the team found the tests achieved 100% species specificity: delta smelts always IDd positively as delta smelts, longfin smelts as longfin smelts, and wakasagi as wakasagi.

They are also easy to use in the field. Currently, if you want a quick and reliable ID result, you generally have to send a sample to a lab, where testing can be expensive and often takes at least a day to complete. Dr. Baerwald says. These tests take less than an hour, and could provide the ability to make close to real-time decisions at a much lower cost, she says.

This will be quite helpful to the Department of Water Resources, which needs to differentiate between these species in order to make sure too many protected fish dont end up pulled into water pumps, Dr. Baerwald says. But she can imagine it proving useful in many other situations, too: to fight wildlife trafficking by quickly IDing rare species, for example, or to make identifications while out in the field.

The team is still working on refining the tests, hoping to provide an option that is quick, inexpensive, easy to use, and non-invasive. Of course, species identification is just the first step in conservationonce you figure out what something is, you still have to work hard to protect it, as evidenced by the fraught story of the delta smelt.

But Dr. Baerwald is excited to see where this innovation leads, and happy that conservation biology can benefit from an advance originally pioneered in a different and better-fundedsphere. You can cross technologies from one field into another, she says. That is a really powerful thing to do.

Image: Envato

See more here:
CRISPR has revolutionized medical research. Will conservation biology be next? - Anthropoce

Fact.MR has adopted a multi-disciplinary approach to shed light on the evolution of the global CRISPR and Cas Genes market during the historical period of 2015 2019. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2020, and key prospects over the forecast period 2020 2026.The CRISPR and Cas Genes market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global CRISPR and Cas Genes market. Further, the presented study offers accurate insights pertaining to the different segments of the Global CRISPR and Cas Genes market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

The global CRISPR and Cas genes market shows stellar future growth prospects, expanding at a CAGR of 21.2% during the forecast period (2020-2026). Extensive rounds of primary and comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the CRISPR and Cas Genes market, both at global and regional levels. The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in theCRISPR and Cas Genes market.

After reading the CRISPR and Cas Genes market report, readers get insight into:

Request for Sample Report with Statistical Info @https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The CRISPR and Cas Genes market report offers an assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period. Key regions covered comprise:

The evaluation of the competitive landscape in the CRISPR and Cas Genes market covers the profile of the following top players:

To expand the understanding of opportunities in the global CRISPR and Cas Genes market report looks at close quarters into the opportunities and new avenues in the following key segments:

In addition to understanding the demand patterns of various end user, the report on the CRISPR and Cas Genes market also enumerates trends expected to attract investments by other various associated industries.

On the basis of Product types, the CRISPR and Cas Genes market report offers insight into major adoption trends for the following segments:

By Application,

The global CRISPR and Cas Genes market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In the coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

For More Detailed Information about Methodology @https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Some important questions that the CRISPR and Cas Genes market report tries to answer exhaustively are:

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; thats why we publish multi-industry global, regional, and country-specific research reports.

Media Release:https://www.factmr.com/media-release/1591/global-crispr-and-cas-genes-market

The rest is here:
Vector-based Systems will Remain Dominant, Accounting for 60% of the Global CRISPR-Cas Genes Market Value - The Cloud Tribune

In May, federal regulators finalized a new biotechnology policy that will bring sweeping changes to the U.S. food system. Dubbed SECURE, the rule revises U.S. Department of Agriculture regulations over genetically engineered plants, automatically exempting many gene-edited crops from government oversight. Companies and labs will be allowed to self-determine whether or not a crop should undergo regulatory review or environmental risk assessment.

Initial responses to this new policy have followed familiar fault lines in the food community. Seed industry trade groups and biotech firms hailed the rule as important to support continuing innovation. Environmental and small farmer NGOs called the USDAs decision shameful and less attentive to public well-being than to agribusinesss bottom line.

But the gene-editing tool CRISPR was supposed to break the impasse in old GM wars by making biotechnology more widely affordable, accessible and thus democratic.

In my research, I study how biotechnology affects transitions to sustainable food systems. Its clear that since 2012 the swelling R&D pipeline of gene-edited grains, fruits and vegetables, fish and livestock has forced U.S. agencies to respond to the so-called CRISPR revolution.

Yet this rule change has a number of people in the food and scientific communities concerned. To me, it reflects the lack of accountability and trust between the public and government agencies setting policies.

The USDA Animal and Plant Health Inspection Service, or APHIS, serves as the dominant U.S. regulator for plant health. Since the mid-1990s, genetically modified crops have typically fallen under APHIS oversight because Agrobacterium, a plant pest, is commonly used as a tool to engineer GM products. Using a plant pest did not prevent many GM crops from being approved. But it did mean that if APHIS suspected a plant pest or noxious weed had been created through genetic engineering, the agency would regulate the biotech product, including its release into the environment, and its import, handling, and interstate movement.

Changes to APHIS regulations began during the Obama administration. In January 2017, the agency released new draft rules. However, the Trump administration withdrew these nine months later after pushback from industry and biotech developers which argued that the rules would stifle innovation.

Last summer, USDA released a revised rule for public comment, which it finalized on May 18, 2020. Most changes go into effect in April 2021.

Hints to how USDA intended to treat gene-edited crops came early on, when Penn States nonbrowning mushrooms and DuPonts waxy corn were approved by APHIS in 2015 and 2016, respectively.

Then in March 2018, USDA Secretary Perdue clarified the agencys stance. USDA does not currently regulate, or have any plans to regulate, plants that could otherwise have been developed through traditional breeding techniques as long as they are developed without the use of a plant pest as the donor or vector and they are not themselves plant pests.

The new SECURE rule establishes several ways for developers to qualify for deregulated status. Included are CRISPR modifications like deletions of sections of the genetic code, tiny substitutions, and introductions of DNA from related species. So, for example, a CRISPRd cauliflower would not be regulated if a chunk of DNA was deleted. But it would still be regulated if CRISPR introduced foreign DNA into cauliflower in a way that USDA believes could turn the product into a plant pest.

Another significant change is that companies and scientists will get to decide for themselves if a new product qualifies for exemption from oversight. APHIS says that developers may consult regulators if at any point they arent sure if a new crop is exempt. However, the agency has already expressed confidence that only about 1% of plants might not qualify for an exemption or for deregulation after an initial review.

Ironically, this policy has begun aligning communities typically at loggerheads in the polarized GM conversation. For example, the UC-based Innovative Genomics Institute, founded by CRISPR co-inventor Jennifer Doudna, wrote in its public comments to APHIS: While we recognize the agencys rationale behind self-determination and desire to provide regulatory relief in order to spur innovation, we are concerned that rather than stimulating innovation, such an undisclosed step may have the effect of dampening trust through the loss of transparency in the development and oversight process.

Meanwhile, GM-watchdog organizations including the National Family Farmers Coalition, Pesticide Action Network and Friends of the Earth issued a joint press statement criticizing a rule that allows industry to self-determine its regulatory status. The new framework, they said, has dealt a devastating blow to the security of farmers livelihoods, the health of their farms and communities, and their ability to build the biodiverse, climate-resilient, and economically robust farming systems that we so urgently need.

My research on democratizing biotechnology has helped me unpack the problematic ways in which democracy is being hitched to technological innovation. When it comes to CRISPR, the public has been told that being cheap, easy to use and free from regulation is a powerful cocktail that makes gene editing intrinsically more democratic.

Like many convenient narratives, there are certain truths to this story. But just as clearly, cheapness is not equivalent to democratic. According to USDA, some 6,150 comments were received on the draft rule during the three-month public feedback period, a window designed to give citizens a say in government policy.

The agency admitted that most letters expressed general opposition to GE products. Of the comments that specifically addressed provisions of the rule, approximately 25 expressed some support for the rule. This means a vast majority of the comments did not. Yet, the USDA disregarded this feedback. Such a lack of civic input can lead to environmental and health concerns being sidelined.

Thoughtful scientists, social movements and governments are now asking if there is an alternative way to regulate engineered food. For example, the Norwegian Biotechnology Advisory Board has set out an ethics-based regulatory framework aimed at advancing genetic technology, while protecting community and environmental health and promoting societal welfare.

In the academic sphere, colleagues in Europe have proposed a framework for responsible innovation. I have developed a set of principles and practices for governing CRISPR based on dialogue with front-line communities who are most affected by the technologies others usher in. Communities dont just have to adopt or refuse technology they can co-create it.

One way to move forward in the U.S. is to take advantage of common ground between sustainable agriculture movements and CRISPR scientists. The struggle over USDA rules suggests that few outside of industry believe self-regulation is fair, wise or scientific.

At present, companies dont even have to notify the USDA of biotech crops they will commercialize. The result, as Greg Jaffe of the Center for Science in the Public Interest told Science, is that government regulators and the public will have no idea what products will enter the market. Farmers and everyone else will pay the price,said Jim Goodman, dairy farmer and board president of the National Family Farm Coalition.

Reclaiming a baseline of accountability, then, is the first step in building public confidence in regulatory systems that work for people as well as science that the public believes in.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Link:
How a new biotech rule will foster distrust with the public and impede progress in science - The Conversation US

CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo,today announced the closing of an underwritten public offering of 6,301,370 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 821,917 shares, at the public offering price of $18.25 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and estimated expenses of the offering, were approximately $115 million.

Goldman Sachs & Co. LLC, Jefferies and SVB Leerink acted as joint book-running managers for the offering.

The shares of common stock were offered by Intellia pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective by, the U.S. Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on June 3, 2020. The final prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or SVB Leerink LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6218, or by email at syndicate@svbleerink.com; or by accessing the SECs website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics

Intellia Therapeuticsis a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Intellias anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in Intellias most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with the SEC, including those contained or incorporated by reference in the final prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements contained in this press release represent Intellias views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Intellia Contacts:

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612lina.li@intelliatx.com

Media:Jennifer Mound SmoterSenior Vice PresidentExternal Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Link:
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase...

]]> The updated alliance provides rights for Regeneron to develop products for more in-vivo CRISPR/Cas9-based therapeutic targets. Credit: PublicDomainPictures from Pixabay.

Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.

The updated alliance also provides rights for Regeneron to develop products for more in-vivo CRISPR / Cas9-based therapeutic targets. The company also gains non-exclusive rights to develop and commercialise ex-vivo gene-edited products.

In turn, Intellia will get an upfront payment of $70m, along with an equity investment of $30m from Regeneron.

Regeneron Pharmaceuticals co-founder, president and chief scientific officer George Yancopoulos said: The Regeneron team works hard to push the boundaries of science and technology, and we believe the precise in-vivo gene insertion capabilities jointly developed with Intellia could be a promising therapeutic platform with significant potential in many diseases, including those that have been historically difficult to treat.

Our parent business intelligence company

Regeneron and Intellia previously leveraged the latters CRISPR / Cas9 platform for targeted insertion of therapeutic proteins and antibodies.

This expansion is intended to leverage jointly-developed targeted transgene insertion capabilities and advance their discovery and development of therapies, including haemophilia A and B treatments.

The partners tested their first CRISPR / Cas9-mediated targeted transgene insertion in the liver of non-human primates. Following the insertion, the animals could produce normal or higher levels of circulating human Factor IX, a blood-clotting protein missing or defective in patients with haemophilia B.

According to the companies, these findings indicate that transgene insertion could offer a functional Factor 9 gene, which encodes for Factor IX.

Intellia Therapeutics CEO and president John Leonard said: We believe that our CRISPR / Cas9-based technology addresses the limitations of current replacement and gene therapy approaches, and importantly, may provide a durable, potentially life-long solution to these genetic diseases.

Under the expanded deal, the term of the companies alliance comes with an extension until April 2024. Regeneron holds an option to renew the collaboration for an additional two years.

Last month, Regeneron announced the repurchase of around $5bn of its common stock directly from Frances Sanofi.

See the original post here:
Regeneron and Intellia to develop new haemophilia therapies - Pharmaceutical Technology

Despite having more coronavirus cases than any other country, America has a testing rate below several countries that have lower per capita rates of the virus.

The slow rollout of testing has crippled us from making more progress and opening up the economy, says Ryan Demmer of the division of epidemiology and community health at the University of Minnesota.

While testing for active infections has much improved since March, tests are still in short supply in some areas around the country. And where tests are readily attainable, results can still take several days.

Now numerous companies are racing to develop rapid at-home tests. Rather than requiring advanced lab equipment for processing, as current tests do, these new ones would use a sample collected at home and, like a pregnancy test, give you a simple positive or negative in less than an hour. (These tests are distinct from the at-home collection kits also being rolled out that require you to send a sample to a lab for processing.)

If these rapid tests prove to be accurate, affordable, and easy to manufacture, they could allow many more Americans to test themselves, even on a regular basis. This could be a huge asset in the fight against the coronavirus, which continues to spread in the US and take thousands of lives a week.

These tools are urgently needed, says Amanda Castel, a doctor and professor of epidemiology at the Milken Institute School of Public Health at George Washington University.

And for the SARS-CoV-2 virus, which causes Covid-19, testing is particularly important, Demmer says, because a lot of the transmission happens from asymptomatic people or presymptomatic people people who dont have any signs of the virus. (In fact, people seem to be most infectious just before they start to have symptoms.)

But there are many caveats to rolling out large-scale, rapid at-home testing for the coronavirus. For example, the results would need to be shared with public health officials to track cases and trace the contacts of people who test positive, and no ones put in place a way to do that yet. And these tests, some of which will likely have lower accuracy than current PCR tests, are also still probably at least a few months away from being available.

For starters, its painfully clear that we need faster, more frequent, and more widely available testing.

The current testing process in the US typically requires a health care worker wearing personal protective equipment (PPE is still in limited supply in some places) to collect a sample. It then needs a lab to analyze it (which takes hours and expensive machines to amplify the genetic signature of the virus). This resource-intensive process has not proved to be scalable to even approach the 500,000 tests per day that experts say the US should be doing at minimum. And the labs processing these tests continue having major backlogs and supply shortages from nasal swabs to the testing machines further hampering wider rollout.

The long waits for results, which still usually take days, have also caused issues.

Before receiving their results, people are advised to self-quarantine just in case. In addition to people not always complying, this lag can also delay identifying the personal contacts of people who are infected.

As Castel, who has studied testing and tracking for HIV infections, notes, Any time you can get someone tested and provide them with their results right then and there, there is an advantage for public health efforts to stop disease transmission. So far, we havent really been able to do this for Covid-19 at any substantial scale.

At best, there are some coronavirus tests that can provide results within a few hours if the test is done on-site (such as at a health care facility that has a testing lab), but their availability is extremely limited. And the accuracy of another test, made by Abbott, which promised answers in less than an hour, has been called into question.

Having a test that people could do without seeing a health care worker in person would also be helpful, saving strain on medical personnel and personal protective equipment.

At-home tests could make it even safer to test people with symptoms while reducing exposure for health care workers, says Emily Toth Martin, an epidemiologist at the University of Michigan School of Public Health. It might also encourage people who are not sure if they are sick to get tested.

In late April, the US Food and Drug Administration began authorizing some at-home collection kits for coronavirus tests; there are now six such kits that have been authorized. These kits let people collect their sample (whether via a nasal swab or saliva) at home before mailing it to a lab. By avoiding a trip to a medical facility to get tested, they can limit spreading the virus if they are infected and reduce their odds of catching it if they are not.

However, these new test collection methods still require lab processing and take several days to receive results. And many are still only available in limited quantities and are being used primarily for front-line health care workers.

We do have technologies that can detect viral particles more quickly and with far less equipment than the mainstream PCR method. In particular, there are two key techniques researchers are currently pursuing.

One method is known as antigen-based testing. These tests look for virus-specific proteins in mucus from nasal swabs and can produce a quick readout, such as a line on a test strip, if the virus is present. (This is in contrast to PCR tests that rely on multiplying genetic material of the virus with expensive machinery and careful laboratory handling before the virus can be detected.)

Antigen testing is already used for rapid tests for strep throat at doctors offices and as part of at-home HIV tests (which also look for antibodies to the virus). The White House has talked up the potential for wide-scale use of these tests, and the FDA authorized the first one in May.

Antigen tests are, however, considered less accurate than the current PCR tests, with some companies estimating their tests miss one in five people who have Covid-19. This might be in part because, unlike the PCR test, it does not multiply the viral particles and so must rely only on the quantity collected in the sample. So they could be especially prone to missing the infection in people who have early infections or who do not collect the sample properly. So some experts suggest these tests would best serve as a quick initial screening; likely cases would then receive a traditional PCR test for confirmation and diagnosis.

Another approach uses CRISPR, the gene-editing technique. It deploys specially designed molecules to find genetic sequences in the SARS-CoV-2 virus and activate compounds to send a signal again, like a line on a test strip if the virus is present. This could be done in about 20 minutes at home. The two most famous scientists in CRISPR technology, Jennifer Doudna of the University of California Berkeley and Feng Zhang of MIT, are each working to bring tests to market that use this process (with Mammoth Biosciences and Sherlock Biosciences, respectively).

Before the pandemic hit, CRISPR technology was already a potential rapid diagnostic tool for other illnesses such as tuberculosis. Results of early studies like the TB one suggest it might have a relatively high accuracy rate, and an early, non-peer-reviewed paper by the researchers at Sherlock Biosciences reports its lab-based CRISPR Covid-19 test has an accuracy similar to PCR tests.

Like the current viral PCR tests, both of these new test types would only look for current infections, not previous ones. Developing a rapid at-home test for previous infection (by looking for coronavirus antibodies) has been less of a priority so far.

I would choose to test for infection at home over a test for antibodies, because it can change decisions that you make that same day to prevent spreading to others, says Toth Martin. For controlling the pandemic, getting accurate viral tests into the hands of people with symptoms has the potential to stop the transmission through a community. That is incredibly valuable.

But just having these tests widely available would not guarantee a slowing of the coronaviruss surge. It would be a convenient way to broaden the availability of tests; however, it needs to be carefully thought out, Castel says. One potential problem with home-based tests is that you could lose the ability to track the virus: who has it and where it is spreading.

Currently, because Covid-19 tests are being run through approved labs, there is a structure in place to collect information about results positive as well as negative ones. This information gets reported to local and state health departments and, ultimately, the federal government. With this data, officials can learn where the virus is and whether its prevalence is increasing or decreasing in certain locations, and know whom to contact to let people whod been exposed to someone infected know they should self-quarantine and maybe seek testing and care.

But if people were able to get quick results from a paper strip at home, there is a real danger of losing this surveillance that is essential to reducing the spread of the virus across the country.

People who tested positive for the virus would need to self-quarantine, and ideally their contacts would need to be traced and notified to also self-isolate. But if theres no doctor, nurse, or health official involved in the process, that tracing and isolation might not happen. Additionally, it would be important for those who receive a positive test result at home to have access to health care, as needed. Without going through a lab or health care system, these messages and connections could easily get lost.

If people were to do their own testing, ideally a procedure would be in place to ensure that the test results get reported to the local health department, Castel says. What exactly this would look like is still not clear. Mammoth Biosciences, which is working on one of the CRISPR tests, has suggested, for example, possibly somehow integrating the test with an app that would report the results anonymously.

And for the patient side, from Castels work on HIV home-based testing, she notes that having a consumer hotline for people to call with questions about taking the test, interpreting their results, and getting connected to health care would also be crucial.

In the rush to get more tests virus-detection tests as well as antibody tests to more people, the FDA has waved through dozens of brand new diagnostics without subjecting them to in-depth scrutiny. Its done so under the Emergency Use Authorization power, which waives the standard, lengthy approval process. The result is that numerous tests have been deployed with sketchy accuracy rates some estimates suggest even current PCR tests might be missing up to a fifth of coronavirus infections (some of this might be due to the tests themselves and some to imperfect collecting and handling methods).

When talking about scaling up a rapid home-based test to potentially the entire country and giving people a tool that, in essence, told them whether or not they were infected (and could infect other people), Demmer says it is imperative these tests be accurate.

These tests have to be good and valid, and I think were a long way from having those, he says. Antigen tests, for example, tend to perform better when looking for bacteria than viruses. And the CRISPR tests are so new, they are still being studied.

The most important area of accuracy would need to be the false-negative rate. A false negative tells a person they dont have the virus when they really do. And in that instance, the person might have a false sense of reassurance and possibly less adherence to social distancing, resulting in further spread of the disease, Castel says.

Demmer agrees. If its going to scale to millions and millions of people, it has to be very close to perfect, to really remove false negatives, he says. (Occasional false positives for infection-detection tests would be less of a setback in controlling the pandemic.) He notes that to ensure this, government regulation of these tests will be essential.

And people taking the test would also need to understand its limitations. It would be important to have a disclaimer to remind users that the test results only reflect someones status for that particular day and time, Castel says. A negative result one day would not guarantee the person would not become infected and infectious in the coming days.

Current health care worker-administered coronavirus tests run about $50 to $100 each. And tests that allow you to collect a sample at home and mail it to a lab cost around $135 to $150.

So although some companies including Ford, Smithfield Foods, and UnitedHealth are starting to test more of their workers as they return to work, these prices make it unrealistic for many businesses to test everyone regularly for an extended period.

Demmer suggests that if new rapid diagnostic tests could approach something closer to $1, they could be deployed virtually everywhere. And many of these rapid tests are looking like they could come in at under $10 each, which would be a vast improvement in making them more accessible.

Demmer acknowledges it might be a pipe dream, but his vision is to have these sorts of rapid tests at every hospital and health clinic and even at the door to every business for employees and customers alike. So if the tests were extremely accurate, a restaurant could conceivably screen everyone and, within several minutes, know whom they could safely allow in. If potential patrons could get screened first, that eliminates the vast majority of your concerns, Demmer says.

Even if rapid tests meet all of these criteria, they are likely still many months away. Of the antigen tests, for example, David Walt, a professor of pathology at Brigham and Womens Hospital, told CNBC that he expects it would probably be four to six months before they would be given FDA authorization.

If and when they do become available, though, he said, I suspect well have pretty good test strips that people will be able to buy like a pack and test themselves every few days or if theyre considering going back to school or work.

As we look ahead to the cold and flu season of the fall and winter, rapid testing could become even more important. I can see these being especially useful in a few months when we might be contending with Covid-19 and other viruses at the same time, Toth Martin says.

And developing rapid at-home tests for these other viruses would be helpful, too, far beyond the pandemic. Id love to see rapid diagnostic tests for all sorts of respiratory viruses, not just SARS-CoV-2, she says. Knowing you have influenza when you thought it might be just a cold could convince you to stay home and not spread it to vulnerable people.

Support Voxs explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.

Visit link:
Covid-19 testing at home: The race to make it easy as a pregnancy test - Vox.com

Research And Development Institutes

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the CRISPR And CRISPR-Associated (Cas) Genes market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207429&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of CRISPR And CRISPR-Associated (Cas) Genes Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 CRISPR And CRISPR-Associated (Cas) Genes Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 CRISPR And CRISPR-Associated (Cas) Genes Market, By Deployment Model

5.1 Overview

6 CRISPR And CRISPR-Associated (Cas) Genes Market, By Solution

6.1 Overview

7 CRISPR And CRISPR-Associated (Cas) Genes Market, By Vertical

7.1 Overview

8 CRISPR And CRISPR-Associated (Cas) Genes Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=207429&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: CRISPR And CRISPR-Associated (Cas) Genes Market Size, CRISPR And CRISPR-Associated (Cas) Genes Market Trends, CRISPR And CRISPR-Associated (Cas) Genes Market Growth, CRISPR And CRISPR-Associated (Cas) Genes Market Forecast, CRISPR And CRISPR-Associated (Cas) Genes Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Excerpt from:
CRISPR And CRISPR-Associated (Cas) Genes Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud...

Research and Development Institutes

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the CRISPR And CRISPR-Associated (Cas) Genes Sales market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=240156&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of CRISPR And CRISPR-Associated (Cas) Genes Sales Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 CRISPR And CRISPR-Associated (Cas) Genes Sales Market, By Deployment Model

5.1 Overview

6 CRISPR And CRISPR-Associated (Cas) Genes Sales Market, By Solution

6.1 Overview

7 CRISPR And CRISPR-Associated (Cas) Genes Sales Market, By Vertical

7.1 Overview

8 CRISPR And CRISPR-Associated (Cas) Genes Sales Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=240156&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: CRISPR And CRISPR-Associated (Cas) Genes Sales Market Size, CRISPR And CRISPR-Associated (Cas) Genes Sales Market Trends, CRISPR And CRISPR-Associated (Cas) Genes Sales Market Growth, CRISPR And CRISPR-Associated (Cas) Genes Sales Market Forecast, CRISPR And CRISPR-Associated (Cas) Genes Sales Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Originally posted here:
CRISPR And CRISPR-Associated (Cas) Genes Sales Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 -...